Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ford Motor Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.58 (market cap $5.07B), while Ford Motor Company trades at $13.87 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 11× ACADIA Pharmaceuticals Inc.'s market cap, and Ford Motor Company pays a 4.29% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | F | |
|---|---|---|
Market Cap | $5.07B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $17.44 |
52-Week Low | $20.06 | $11.21 |
Enterprise Value | $4.19B | $187.71B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Ford (F) trades at $13.86, down 1.14%, with a bearish technical signal. Recent earnings show volatility, with Q1 and Q2 2026 beats but a Q4 2025 miss. The company reported a net loss of $8.18B for 2025, though operating cash flow remains strong at $21.28B. News highlights the upcoming affordable Fathom EV truck priced at $28,350, targeting market share gains amid high vehicle prices.
The outlook is mixed: analyst consensus is a Buy with a $16.18 target, offering potential upside, but risks include intense EV competition, profitability challenges, and high debt levels. The stock's low P/E of 11.84 may attract value investors, but execution on new models is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
